


Figure 1
Mechanism of the IgE-mediated Allergic Disease Pathway

Sensitization	Triggering	Manifestation
---------------	------------	---------------







Figure 3




Figure 4




Figure 5




Figure 6A




Figure 6B




Figure 6C





Figure 7




Cell line: mIgE.Fc_γ Ramos
Antibodies: purified guinea pig anti-IgE-EMPD IgG

SEQ ID NO:	88	89	90	91	92	93	Xolair
EC ₅₀ (ng/mL)	303.8	345.3	277.5	403.9	536	302	121.4


Figure 8

E/T=1:30



Target cell: mlgE.Fc_L Ramos cells
Effector cell: IL-2-treated mouse splenic cells
Antibodies: purified guinea pig anti-IgE EMPD IgG at 10 µg/mL

Figure 9






Figure11




Figure 12





Figure 13





Figure 15
Experimental Protocol for Efficacy Evaluation of IgE-EMPD Vaccine Formulations On Sensitization/Recall Responses in Human IGHE Knockin Hybrid Mice



- Animals: F1 offspring (HuIGHE x Balb/c).
- Groups: Placebo and vaccination groups.
- Vaccine dose: Immunize on weeks 3, 6, and 8 with a dose of 40 µg or adjuvant placebo by *i.m.* route.
- Allergen: Sensitize on week 0 with 50 µg papain/TiterMax Gold adjuvant by subcutaneous route and recall on week 12 with 50 µg papain/PBS solution via footpad.

Figure 16




Figure 17




Figure 18A




Figure 18B




Figure 19




Figure 20

Antibody titers [$\log_{10}(\text{dilution factor})$] to SEQ ID NO: 5




Figure 21

